Regen Biopharma Stock Probability Of Bankruptcy
| RGBP Stock | USD 0.20 0.02 9.09% |
Regen |
Regen BioPharma Company probability of distress Analysis
Regen BioPharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Regen BioPharma Probability Of Bankruptcy | Over 88% |
Most of Regen BioPharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regen BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Regen BioPharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Regen BioPharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Regen BioPharma financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Regen BioPharma has a Probability Of Bankruptcy of 88%. This is 103.28% higher than that of the Healthcare sector and 60.47% higher than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 120.94% lower than that of the firm.
Regen Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regen BioPharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Regen BioPharma could also be used in its relative valuation, which is a method of valuing Regen BioPharma by comparing valuation metrics of similar companies.Regen BioPharma is currently under evaluation in probability of bankruptcy category among its peers.
Regen Fundamentals
| Return On Asset | -0.76 | |||
| Profit Margin | 6.09 % | |||
| Operating Margin | (2.96) % | |||
| Current Valuation | 22.4 M | |||
| Shares Outstanding | 5.05 B | |||
| Shares Owned By Insiders | 0.06 % | |||
| Price To Sales | 89.73 X | |||
| Revenue | 235.52 K | |||
| Gross Profit | 235.52 K | |||
| EBITDA | 2.44 M | |||
| Net Income | 2.44 M | |||
| Cash And Equivalents | 110.99 K | |||
| Total Debt | 1.58 M | |||
| Debt To Equity | 1.25 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (606.92 K) | |||
| Beta | 3.36 | |||
| Market Capitalization | 10.1 M | |||
| Total Asset | 559 K | |||
| Retained Earnings | (17.78 M) | |||
| Working Capital | (478 K) | |||
| Current Asset | 171 K | |||
| Current Liabilities | 649 K | |||
| Z Score | -26.6 | |||
| Net Asset | 559 K |
About Regen BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regen BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regen BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regen BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Regen BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regen BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regen BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Regen Pink Sheet
| 0.8 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.74 | BKRKY | Bank Rakyat | PairCorr |
| 0.73 | PBCRY | Bank Central Asia | PairCorr |
| 0.73 | PTBRY | Bank Negara Indonesia | PairCorr |
| 0.69 | PPERF | Bank Mandiri Persero | PairCorr |
The ability to find closely correlated positions to Regen BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regen BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regen BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regen BioPharma to buy it.
The correlation of Regen BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regen BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regen BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regen BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.